Which has higher valuation and earnings, LIVN or ZBH?

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 2.86 -$242.47M $1.95 37.11 Zimmer Biomet $8.23B 2.06 $705.20M $3.85 22.73

Is LIVN or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Zimmer Biomet's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media favor LIVN or ZBH?

In the previous week, Zimmer Biomet had 14 more articles in the media than LivaNova. MarketBeat recorded 15 mentions for Zimmer Biomet and 1 mentions for LivaNova. Zimmer Biomet's average media sentiment score of 1.20 beat LivaNova's score of 0.26 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zimmer Biomet 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, LIVN or SOLV?

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 2.86 -$242.47M $1.95 37.11 Solventum $8.33B 1.69 $1.56B $8.16 9.93

Is LIVN or SOLV more profitable?

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Solventum 17.33% 23.51% 7.63%

Does the media refer more to LIVN or SOLV?

In the previous week, Solventum had 5 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Solventum and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.26 beat Solventum's score of -0.04 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LIVN or SNN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 2.86 -$242.47M $1.95 37.11 Smith & Nephew SNATS $6.16B 2.12 $625M N/A N/A

Does the media favor LIVN or SNN?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for Smith & Nephew SNATS and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.26 beat Smith & Nephew SNATS's score of -1.00 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher earnings & valuation, PEN or LIVN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.98 $177.69M $4.34 73.85 LivaNova $1.39B 2.86 -$242.47M $1.95 37.11

Is PEN or LIVN more profitable?

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% LivaNova 7.48% 16.48% 7.59%

Does the media prefer PEN or LIVN?

In the previous week, Penumbra had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for Penumbra and 1 mentions for LivaNova. Penumbra's average media sentiment score of 0.73 beat LivaNova's score of 0.26 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, LIVN or GKOS?

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 2.86 -$242.47M $1.95 37.11 Glaukos $507.44M 14.44 -$187.69M -$3.28 N/A

Is LIVN or GKOS more profitable?

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Glaukos -34.34% -6.92% -5.25%

Does the media prefer LIVN or GKOS?

In the previous week, Glaukos had 2 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Glaukos and 1 mentions for LivaNova. Glaukos' average media sentiment score of 0.37 beat LivaNova's score of 0.26 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

LivaNova (LIVN) Competitors

$72.36 -1.36 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$72.30 -0.06 (-0.09%)

As of 04:16 PM Eastern

Compare

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy LivaNova stock or one of its competitors? MarketBeat compares LivaNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LivaNova include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does LivaNova compare to Zimmer Biomet?

LivaNova (NASDAQ:LIVN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Zimmer Biomet has a net margin of 9.05% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Zimmer Biomet	9.05%	13.24%	7.28%

LivaNova currently has a consensus target price of $79.38, suggesting a potential upside of 9.69%. Zimmer Biomet has a consensus target price of $102.70, suggesting a potential upside of 17.37%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
Zimmer Biomet	$8.23B	2.06	$705.20M	$3.85	22.73

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

In the previous week, Zimmer Biomet had 14 more articles in the media than LivaNova. MarketBeat recorded 15 mentions for Zimmer Biomet and 1 mentions for LivaNova. Zimmer Biomet's average media sentiment score of 1.20 beat LivaNova's score of 0.26 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet beats LivaNova on 10 of the 17 factors compared between the two stocks.

How does LivaNova compare to Solventum?

LivaNova (NASDAQ:LIVN) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

LivaNova has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

LivaNova currently has a consensus target price of $79.38, indicating a potential upside of 9.69%. Solventum has a consensus target price of $84.25, indicating a potential upside of 3.93%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe LivaNova is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Solventum	17.33%	23.51%	7.63%

97.6% of LivaNova shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
Solventum	$8.33B	1.69	$1.56B	$8.16	9.93

In the previous week, Solventum had 5 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Solventum and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.26 beat Solventum's score of -0.04 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

LivaNova and Solventum tied by winning 8 of the 16 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

LivaNova (NASDAQ:LIVN) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

LivaNova has a net margin of 7.48% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.48% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Smith & Nephew SNATS	N/A	N/A	N/A

97.6% of LivaNova shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LivaNova has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
Smith & Nephew SNATS	$6.16B	2.12	$625M	N/A	N/A

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for Smith & Nephew SNATS and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.26 beat Smith & Nephew SNATS's score of -1.00 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

LivaNova presently has a consensus target price of $79.38, suggesting a potential upside of 9.69%. Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential upside of 0.98%. Given LivaNova's stronger consensus rating and higher possible upside, research analysts clearly believe LivaNova is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

LivaNova beats Smith & Nephew SNATS on 10 of the 14 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Penumbra currently has a consensus price target of $361.33, suggesting a potential upside of 12.74%. LivaNova has a consensus price target of $79.38, suggesting a potential upside of 9.69%. Given Penumbra's higher possible upside, research analysts clearly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.98	$177.69M	$4.34	73.85
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11

In the previous week, Penumbra had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for Penumbra and 1 mentions for LivaNova. Penumbra's average media sentiment score of 0.73 beat LivaNova's score of 0.26 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Penumbra has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
LivaNova	7.48%	16.48%	7.59%

88.9% of Penumbra shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Penumbra beats LivaNova on 11 of the 16 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

LivaNova (NASDAQ:LIVN) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

LivaNova presently has a consensus target price of $79.38, suggesting a potential upside of 9.69%. Glaukos has a consensus target price of $146.17, suggesting a potential upside of 17.13%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Glaukos	-34.34%	-6.92%	-5.25%

LivaNova has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
Glaukos	$507.44M	14.44	-$187.69M	-$3.28	N/A

In the previous week, Glaukos had 2 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Glaukos and 1 mentions for LivaNova. Glaukos' average media sentiment score of 0.37 beat LivaNova's score of 0.26 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Glaukos beats LivaNova on 9 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.05B	$7.39B	$6.49B	$12.46B
Dividend Yield	N/A	1.19%	2.67%	5.34%
P/E Ratio	37.11	37.72	20.30	22.08
Price / Sales	2.86	74.36	517.33	112.57
Price / Cash	15.24	24.88	42.35	57.17
Price / Book	3.29	7.04	9.73	6.37
Net Income	-$242.47M	$159.22M	$3.56B	$337.36M
7 Day Performance	-1.95%	-2.42%	-3.19%	-3.07%
1 Month Performance	25.65%	3.38%	-0.11%	0.37%
1 Year Performance	61.34%	0.90%	25.29%	27.87%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.9069 of 5 stars	$72.36 -1.8%	$79.38 +9.7%	+65.7%	$4.05B	$1.39B	37.11	3,300
ZBH Zimmer Biomet	4.5119 of 5 stars	$82.83 +0.6%	$102.70 +24.0%	-5.3%	$15.93B	$8.41B	21.51	17,000	Positive News Insider Trade
SOLV Solventum	2.63 of 5 stars	$75.97 +1.4%	$84.25 +10.9%	+9.7%	$12.98B	$8.26B	9.31	20,000
SNN Smith & Nephew SNATS	1.8682 of 5 stars	$29.47 -0.8%	$30.93 +5.0%	+5.5%	$12.59B	$6.16B	N/A	16,988	Negative News Analyst Downgrade
PEN Penumbra	2.074 of 5 stars	$318.75 +0.1%	$361.33 +13.4%	+25.8%	$12.52B	$1.40B	73.44	4,700	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does LivaNova compare to Zimmer Biomet?

Summary

How does LivaNova compare to Solventum?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does LivaNova compare to Zimmer Biomet?

Is LIVN or ZBH more profitable?

Do analysts recommend LIVN or ZBH?

Which has higher valuation and earnings, LIVN or ZBH?

Do institutionals & insiders have more ownership in LIVN or ZBH?

Which has more volatility and risk, LIVN or ZBH?

Does the media favor LIVN or ZBH?

Summary

How does LivaNova compare to Solventum?

Which has more risk & volatility, LIVN or SOLV?

Do analysts rate LIVN or SOLV?

Is LIVN or SOLV more profitable?

Do institutionals & insiders believe in LIVN or SOLV?

Which has higher earnings and valuation, LIVN or SOLV?

Does the media refer more to LIVN or SOLV?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Is LIVN or SNN more profitable?

Do insiders and institutionals have more ownership in LIVN or SNN?

Which has more volatility and risk, LIVN or SNN?

Which has higher valuation & earnings, LIVN or SNN?

Does the media favor LIVN or SNN?

Do analysts recommend LIVN or SNN?

Summary

How does LivaNova compare to Penumbra?

Do analysts prefer PEN or LIVN?

Which has higher earnings & valuation, PEN or LIVN?

Does the media prefer PEN or LIVN?

Which has more risk and volatility, PEN or LIVN?

Is PEN or LIVN more profitable?

Do institutionals & insiders have more ownership in PEN or LIVN?

Summary

How does LivaNova compare to Glaukos?

Do analysts prefer LIVN or GKOS?

Is LIVN or GKOS more profitable?

Which has more risk & volatility, LIVN or GKOS?

Do institutionals and insiders have more ownership in LIVN or GKOS?

Which has preferable valuation & earnings, LIVN or GKOS?

Does the media prefer LIVN or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools